AUXLY CANNABIS GROUP INC (XLY.CA) Fundamental Analysis & Valuation

TSX:XLY • CA05335P1099

0.125 CAD
+0.01 (+4.17%)
Last: Mar 11, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This XLY.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to XLY. XLY was compared to 34 industry peers in the Pharmaceuticals industry. XLY has an average financial health and profitability rating. An interesting combination arises when we look at growth and value: XLY is growing strongly while it also seems undervalued.


Dividend Valuation Growth Profitability Health

6

1. XLY.CA Profitability Analysis

1.1 Basic Checks

  • In the past year XLY was profitable.
  • In the past year XLY had a positive cash flow from operations.
  • In the past 5 years XLY always reported negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: XLY reported negative operating cash flow in multiple years.
XLY.CA Yearly Net Income VS EBIT VS OCF VS FCFXLY.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

  • With an excellent Return On Assets value of 16.40%, XLY belongs to the best of the industry, outperforming 97.06% of the companies in the same industry.
  • With an excellent Return On Equity value of 26.28%, XLY belongs to the best of the industry, outperforming 97.06% of the companies in the same industry.
  • XLY's Return On Invested Capital of 8.12% is amongst the best of the industry. XLY outperforms 91.18% of its industry peers.
Industry RankSector Rank
ROA 16.4%
ROE 26.28%
ROIC 8.12%
ROA(3y)-20.84%
ROA(5y)-18.51%
ROE(3y)-81.82%
ROE(5y)-60.99%
ROIC(3y)N/A
ROIC(5y)N/A
XLY.CA Yearly ROA, ROE, ROICXLY.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

  • XLY's Profit Margin of 31.05% is amongst the best of the industry. XLY outperforms 97.06% of its industry peers.
  • XLY has a Operating Margin of 17.28%. This is in the better half of the industry: XLY outperforms 79.41% of its industry peers.
  • Looking at the Gross Margin, with a value of 52.00%, XLY is in the better half of the industry, outperforming 79.41% of the companies in the same industry.
  • In the last couple of years the Gross Margin of XLY has grown nicely.
Industry RankSector Rank
OM 17.28%
PM (TTM) 31.05%
GM 52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.45%
GM growth 5YN/A
XLY.CA Yearly Profit, Operating, Gross MarginsXLY.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. XLY.CA Health Analysis

2.1 Basic Checks

  • XLY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • XLY has more shares outstanding than it did 1 year ago.
  • XLY has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for XLY has been reduced compared to a year ago.
XLY.CA Yearly Shares OutstandingXLY.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
XLY.CA Yearly Total Debt VS Total AssetsXLY.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of -0.02, we must say that XLY is in the distress zone and has some risk of bankruptcy.
  • XLY has a Altman-Z score (-0.02) which is in line with its industry peers.
  • XLY has a debt to FCF ratio of 4.16. This is a neutral value as XLY would need 4.16 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 4.16, XLY belongs to the best of the industry, outperforming 85.29% of the companies in the same industry.
  • A Debt/Equity ratio of 0.30 indicates that XLY is not too dependend on debt financing.
  • XLY has a Debt to Equity ratio of 0.30. This is comparable to the rest of the industry: XLY outperforms 58.82% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF 4.16
Altman-Z -0.02
ROIC/WACC1
WACC8.13%
XLY.CA Yearly LT Debt VS Equity VS FCFXLY.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 1.93 indicates that XLY should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.93, XLY is in line with its industry, outperforming 58.82% of the companies in the same industry.
  • XLY has a Quick Ratio of 1.05. This is a normal value and indicates that XLY is financially healthy and should not expect problems in meeting its short term obligations.
  • XLY has a Quick ratio (1.05) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.93
Quick Ratio 1.05
XLY.CA Yearly Current Assets VS Current LiabilitesXLY.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. XLY.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 151.10% over the past year.
  • Looking at the last year, XLY shows a very strong growth in Revenue. The Revenue has grown by 27.38%.
  • XLY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 71.07% yearly.
EPS 1Y (TTM)151.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%433.33%
Revenue 1Y (TTM)27.38%
Revenue growth 3Y13.43%
Revenue growth 5Y71.07%
Sales Q2Q%19.57%

3.2 Future

  • The Earnings Per Share is expected to grow by 53.92% on average over the next years. This is a very strong growth
  • XLY is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.57% yearly.
EPS Next Y210.75%
EPS Next 2Y53.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year14.35%
Revenue Next 2Y10.97%
Revenue Next 3Y26.12%
Revenue Next 5Y22.57%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
XLY.CA Yearly Revenue VS EstimatesXLY.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
XLY.CA Yearly EPS VS EstimatesXLY.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -0.05 -0.1 -0.15

More info and screens

Find the best growth stocksShow best growing peers

8

4. XLY.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 3.13, the valuation of XLY can be described as very cheap.
  • 91.18% of the companies in the same industry are more expensive than XLY, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of XLY to the average of the S&P500 Index (26.15), we can say XLY is valued rather cheaply.
  • The Price/Forward Earnings ratio is 12.38, which indicates a correct valuation of XLY.
  • Based on the Price/Forward Earnings ratio, XLY is valued a bit cheaper than 79.41% of the companies in the same industry.
  • XLY's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.27.
Industry RankSector Rank
PE 3.13
Fwd PE 12.38
XLY.CA Price Earnings VS Forward Price EarningsXLY.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, XLY is valued cheaper than 88.24% of the companies in the same industry.
  • XLY's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. XLY is cheaper than 73.53% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.77
EV/EBITDA 5.73
XLY.CA Per share dataXLY.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.02 0.04 0.06 0.08 0.1

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of XLY may justify a higher PE ratio.
  • A more expensive valuation may be justified as XLY's earnings are expected to grow with 53.92% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y53.92%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. XLY.CA Dividend Analysis

5.1 Amount

  • No dividends for XLY!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

XLY.CA Fundamentals: All Metrics, Ratios and Statistics

AUXLY CANNABIS GROUP INC

TSX:XLY (3/11/2026, 7:00:00 PM)

0.125

+0.01 (+4.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13
Earnings (Next)03-26
Inst Owners0.01%
Inst Owner ChangeN/A
Ins Owners5.66%
Ins Owner ChangeN/A
Market Cap170.88M
Revenue(TTM)146.00M
Net Income(TTM)45.34M
Analysts80
Price Target0.26 (108%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1150%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.89%
Valuation
Industry RankSector Rank
PE 3.13
Fwd PE 12.38
P/S 1.17
P/FCF 10.77
P/OCF 9.2
P/B 0.99
P/tB 1.19
EV/EBITDA 5.73
EPS(TTM)0.04
EY32%
EPS(NY)0.01
Fwd EY8.08%
FCF(TTM)0.01
FCFY9.28%
OCF(TTM)0.01
OCFY10.86%
SpS0.11
BVpS0.13
TBVpS0.11
PEG (NY)0.01
PEG (5Y)N/A
Graham Number0.34
Profitability
Industry RankSector Rank
ROA 16.4%
ROE 26.28%
ROCE 11.28%
ROIC 8.12%
ROICexc 9.41%
ROICexgc 11.05%
OM 17.28%
PM (TTM) 31.05%
GM 52%
FCFM 10.87%
ROA(3y)-20.84%
ROA(5y)-18.51%
ROE(3y)-81.82%
ROE(5y)-60.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.45%
GM growth 5YN/A
F-Score7
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF 4.16
Debt/EBITDA 1.42
Cap/Depr 25.18%
Cap/Sales 1.85%
Interest Coverage 250
Cash Conversion 51.64%
Profit Quality 34.99%
Current Ratio 1.93
Quick Ratio 1.05
Altman-Z -0.02
F-Score7
WACC8.13%
ROIC/WACC1
Cap/Depr(3y)27.93%
Cap/Depr(5y)61.49%
Cap/Sales(3y)4.52%
Cap/Sales(5y)11.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)151.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%433.33%
EPS Next Y210.75%
EPS Next 2Y53.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)27.38%
Revenue growth 3Y13.43%
Revenue growth 5Y71.07%
Sales Q2Q%19.57%
Revenue Next Year14.35%
Revenue Next 2Y10.97%
Revenue Next 3Y26.12%
Revenue Next 5Y22.57%
EBIT growth 1Y204.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year772.58%
EBIT Next 3Y106.86%
EBIT Next 5Y66%
FCF growth 1Y4857.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y201.87%
OCF growth 3YN/A
OCF growth 5YN/A

AUXLY CANNABIS GROUP INC / XLY.CA FAQ

What is the ChartMill fundamental rating of AUXLY CANNABIS GROUP INC (XLY.CA) stock?

ChartMill assigns a fundamental rating of 6 / 10 to XLY.CA.


Can you provide the valuation status for AUXLY CANNABIS GROUP INC?

ChartMill assigns a valuation rating of 8 / 10 to AUXLY CANNABIS GROUP INC (XLY.CA). This can be considered as Undervalued.


Can you provide the profitability details for AUXLY CANNABIS GROUP INC?

AUXLY CANNABIS GROUP INC (XLY.CA) has a profitability rating of 6 / 10.


Can you provide the financial health for XLY stock?

The financial health rating of AUXLY CANNABIS GROUP INC (XLY.CA) is 5 / 10.